Therapy News and Research

RSS

Pediatric cancer charities collaborate to create new treatments for children with neuroblastoma

Solving Kids' Cancer, along with U.K.-based charities Neuroblastoma Alliance UK, J-A-C-K, and other European organizations have aligned forces to improve access to promising clinical trials for children with high-risk neuroblastoma in North America, the U.K. and Europe.

5 Mar 2013

Scientists discover how to detect abnormal brain rhythms associated with Parkinson's

A team of scientists and clinicians at UC San Francisco has discovered how to detect abnormal brain rhythms associated with Parkinson's by implanting electrodes within the brains of people with the disease.

5 Mar 2013

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).

5 Mar 2013

HIV infection may increase risk of acute myocardial infarction

A study that analyzed data from more than 82,000 veterans suggests that infection with the human immunodeficiency virus (HIV) was associated with an increased risk of acute myocardial infarction (AMI, heart attack) beyond what is explained by recognized risk factors, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.

4 Mar 2013

Positive results from NeuroDerm ND0612 Phase I trial on Parkinson's

NeuroDerm, Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.

4 Mar 2013

Autistic children with severe language delay achieve phrase or fluent speech by age eight

New findings published in Pediatrics (Epub ahead of print) by the Kennedy Krieger Institute's Center for Autism and Related Disorders reveal that 70 percent of children with autism spectrum disorders (ASD) who have a history of severe language delay, achieved phrase or fluent speech by age eight.

4 Mar 2013

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).

4 Mar 2013

Older patients with head and neck cancers less likely to die in high-volume hospitals

A study of older patients with advanced head and neck cancers has found that where they were treated significantly influenced their survival.

4 Mar 2013

Prompt antiretroviral therapy may help infants clear the HIV and achieve long-term remission

A team of researchers from Johns Hopkins Children's Center, the University of Mississippi Medical Center and the University of Massachusetts Medical School describe the first case of a so-called "functional cure" in an HIV-infected infant. The finding, the investigators say, may help pave the way to eliminating HIV infection in children.

4 Mar 2013

Study identifies two gene mutations that lead to death of nerve cells in ALS

A study led by St. Jude Children's Research Hospital has discovered mutations in two genes that lead to the death of nerve cells in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and related degenerative diseases.

4 Mar 2013

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

4 Mar 2013

UNC1215 chemical probe can help investigate L3MBTL3 methyl-lysine reader domain

In an article published as the cover story of the March 2013 issue of Nature Chemical Biology, Lindsey James, PhD, research assistant professor in the lab of Stephen Frye, Fred Eshelman Distinguished Professor in the UNC School of Pharmacy and member of the UNC Lineberger Comprehensive Cancer Center, announced the discovery of a chemical probe that can be used to investigate the L3MBTL3 methyl-lysine reader domain.

3 Mar 2013

Melanoma tumours deliberately create conditions that knock out body's premier immune defence

New research in the Journal of Clinical Investigation reveals that tumours in melanoma patients deliberately create conditions that knock out the body's 'premier' immune defence and instead attract a weaker immune response unable to kill off the tumour's cancerous cells.

2 Mar 2013

Elekta launches Versa HD system to treat cancers

During a live global event, Elekta announced the launch of Versa HD, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers.

From Elekta 2 Mar 2013

PDL BioPharma fourth quarter total revenues increase to $86.0 million

PDL BioPharma, Inc. (PDL) today reported financial results for the fourth quarter and full year ended December 31, 2012.

2 Mar 2013

Study shows how theranostic nanoparticles can effectively deliver cancer drugs to tumour cells

Tiny particles filled with a drug could be a new tool for treating cancer in the future. A new study published by Swedish scientists in Particle & Particle Systems Characterization shows how such nanoparticles can be combined to secure the effective delivery of cancer drugs to tumour cells - and how they can be given properties to make them visible in MR scanners and thus rendered trackable.

1 Mar 2013

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announced that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial.

1 Mar 2013

Scientists take important step toward designing a uniform protocol for microbiome research

Earth Day may be more than a month away, but another, more personal, ecosystem has been shown to also be worth protecting-within our bodies are communities of microbes that affect the behavior of human cells hosting them.

1 Mar 2013

Oraya Therapy safe and effective for patients with wet AMD

Oraya Therapeutics, Inc. today announced that one of the patients who successfully was treated for wet age-related macular degeneration (AMD) with Oraya Therapy during the INTREPID clinical trial has released data showing he has experienced significant, sustained vision improvement more than two years after treatment in his right eye, without any subsequent anti-vascular endothelial growth factor (anti-VEGF) injections or other treatment.

1 Mar 2013

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI).

1 Mar 2013

Therapy News and Research

Pediatric cancer charities collaborate to create new treatments for children with neuroblastoma

Scientists discover how to detect abnormal brain rhythms associated with Parkinson's

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

HIV infection may increase risk of acute myocardial infarction

Positive results from NeuroDerm ND0612 Phase I trial on Parkinson's

Autistic children with severe language delay achieve phrase or fluent speech by age eight

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Older patients with head and neck cancers less likely to die in high-volume hospitals

Prompt antiretroviral therapy may help infants clear the HIV and achieve long-term remission

Study identifies two gene mutations that lead to death of nerve cells in ALS

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

UNC1215 chemical probe can help investigate L3MBTL3 methyl-lysine reader domain

Melanoma tumours deliberately create conditions that knock out body's premier immune defence

Elekta launches Versa HD system to treat cancers

PDL BioPharma fourth quarter total revenues increase to $86.0 million

Study shows how theranostic nanoparticles can effectively deliver cancer drugs to tumour cells

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Scientists take important step toward designing a uniform protocol for microbiome research

Oraya Therapy safe and effective for patients with wet AMD

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News